Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the ...

Learn about idiopathic pulmonary fibrosis, its symptoms, diagnosis, and treatment options for managing this lung disease.

The company’s stock price has dropped to around $1.38 per share after its IPF therapy trial was stopped for safety.

The new chief medical officer of the Pulmonary Fibrosis Foundation speaks about patients in rural areas, research ...

The UK IPF Registry has provided new insights into the evolving landscape of idiopathic pulmonary fibrosis management.

The trial, dubbed BEACON-IPF, was assessing the biotech’s lead candidate, an oral small molecule called bexotegrast. The ...

Idiopathic pulmonary fibrosis (IPF) and diabetes mellitus do not appear to have a causal association, according to study findings published in Thorax.

The following is a summary of "Quality of life in idiopathic pulmonary fibrosis in Latin American countries," published in ...

Citi lowered the firm’s price target on Pliant Therapeutics (PLRX) to $1.50 from $4 and keeps a Neutral rating on the shares. The company ...

Cantor Fitzgerald reinstated coverage of Pliant Therapeutics (PLRX) with a Neutral rating and no price target The company is discontinuing the ...

Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the trial's independent ...